Group B Streptococcus
Infection Treatment Market: Overview
·
Group B streptococcus (GBS) infection, also known as group B
strep infection, is a type of bacterial infection that can be found in the
digestive and lower reproductive tracts of both men and women. About 1 in 4
pregnant women carries or is colonized with group B streptococcus. As per the
WHO, group B streptococcus infection causes an estimated 150,000 preventable
still births and infant deaths every year. Around 21.7 million pregnant women carry
this bacteria, according to the first global study of group B strep. Most of
them are currently unidentified and untreated. An estimated 1 in 5 pregnant
women around the world carries the group B streptococcus bacteria, which is a
major yet preventable cause of maternal and infant ill-health globally.
Read Report Overview: https://www.transparencymarketresearch.com/group-b-streptococcus-gbs-infection-treatment-market.html
Key Drivers, Restrains,
and Opportunities of Global Group B Streptococcus Infection Treatment Market
·
There are three types of perinatal group B streptococcus
diseases, each with their own prevention challenges. They are prenatal-onset
GBS disease (before birth), early-onset GBS disease (birth through the first
week of life), and late-onset GBS disease (over one week of age through several
months of age). A study by the London School of Hygiene and Tropical Medicine
estimated that out of 410,000 group B streptococcus cases every year, at least
147,000 stillbirths and infant deaths are estimated to occur globally. Africa
had the highest burden, with 54% of estimated cases and 65% of stillbirths and
infant deaths. A rise in the prevalence of group B streptococcus infections and
the rate of new infections is likely to drive the global group b streptococcus
infection treatment market. Furthermore, an increase in modes of transmission
of the infectious disease and lack of cleanliness in developing regions are
estimated to propel the group B streptococcus infection treatment market in the
region.
Request a Sample of Group B
Streptococcus Infection Treatment Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=64904
Global Group B
Streptococcus Infection Treatment Market: Segmentation
·
The global group B streptococcus infection treatment market can
be segmented based on GBS type, route of administration, drug molecule,
distribution channel, and region. In terms of type of GBS type, the global
market can be categorized into prenatal-onset GBS disease, early-onset GBS
disease, and late-onset GBS disease. Based on route of administration, the
global group B streptococcus infection treatment market can be bifurcated into
oral and parenteral. In terms of drug molecule, the global group B
streptococcus infection treatment market can be divided into small molecule,
vaccines, and others. Current group B streptococcus prevention focuses on
administering antibiotics to women in labor, with an aim to reduce the disease
in infants at delivery. Several vaccines to prevent group B streptococcus are
in development; however, none is currently available. Based on distribution
channel, the global group B streptococcus infection treatment market can be
classified into hospital pharmacies, retail pharmacies, and online pharmacies.
The retail pharmacies segment accounted for a considerable share of the group B
streptococcus infection treatment market due to the availability of generic
drugs.
Enquiry before Buying Group B
Streptococcus Infection Treatment Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=64904
Global Group B
Streptococcus Infection Treatment Market: Regional Analysis
·
In terms of region, the global group B streptococcus infection
treatment market can be segmented into North America (U.S. and Canada), Europe
(U.K., Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan,
India, China, Australia & New Zealand, and Rest of Asia Pacific), Latin
America (Mexico, Brazil, and Rest of Latin America), and Middle East &
Africa (Saudi Arabia, South Africa, Israel, and Rest of Middle East and
Africa). Prevalence of group B streptococcus infection is higher in Asia
Pacific and Middle East & Africa as compared to that in North America and
Europe. According to statistics published by the World Health Organization in
2017, the top five countries by numbers (to nearest 100) of pregnant women
colonized were: India (2,466,500), China (1,934,900), Nigeria (1,060,000), the
U.S. (942,800), and Indonesia (799,100). However, in the U.S., it is
recommended that women be screened for group B streptococcus during weeks 35 to
37 of pregnancy. Pregnant women testing positive are administered an
intravenous antibiotic before delivery to prevent group B streptococcus, which
could manifest shortly after birth (early onset disease). In developing
countries, the infrastructure to provide screening and preventative antibiotics
is either nonexistent or limited, resulting in much higher observed group B
streptococcus disease burden in babies.
Pre-book Group B
Streptococcus Infection Treatment Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=64904<ype=S
Key Players Operating in
Global Group B Streptococcus Infection Treatment Market
Key players developing
therapeutics for group B streptococcus infections are Pfizer Inc., Alopexx
Pharmaceuticals, LLC, Wellstat Vaccines LLC, Minervax ApS, Novartis, GlaxoSmithKline,
and other prominent players. In 2017, Pfizer started phase I/II trial of its
group B streptococcus conjugate vaccine named PF-06760805, which incorporates
at least five serotypes of group B streptococcus and could prevent
approximately 95% of group B streptococcus disease in infants via maternal
immunization.
More Trending
Reports by Transparency Market Research:
https://www.prnewswire.com/news-releases/rise-in-prevalence-of-functional-gi-tract-disorders-to-support-growth-of-parenteral-nutrition-market-says-tmr-301338622.html
https://www.prnewswire.com/news-releases/global-customized-procedure-trays-market-to-grow-as-the-medical-industry-acquires-research-excellence-says-tmr-301210766.html
https://www.prnewswire.com/news-releases/technological-strides-in-bladder-scanners-market-help-clinicians-advance-care-for-patients-with-urinary-tract-infections-valuation-to-touch-mark-of-us-210-0-mn-by-2026-tmr-301213972.html
About Us
Transparency Market Research is a global market intelligence
company providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. Our experienced team
of analysts, researchers, and consultants use proprietary data sources and
various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and information.
With a broad research and analysis capability, Transparency Market Research
employs rigorous primary and secondary research techniques in developing
distinctive data sets and research material for business reports.
Contact
Transparency Market Research,
90 Sate Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com/
